| 2023-09-06 | 8-K | 10.1 | Revolving Credit Loan Agreement, dated as of September 5, 2023, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank |
|---|
| 2023-08-11 | 10-Q | 10.1 | Amendment Number 3 to the Amended and Restated 2007 Long-Term Incentive Compensation Plan, incorporated herein by reference to Appendix A of the Company’s Schedule 14A (File No.: 001-33637) as filed with the SEC on March 15, 2023 and approved by the Company's shareholders on April 25, 2023. |
|---|
| 2023-05-12 | 10-Q | 10.5 | Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between John M. Hamm and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.15 of the Company’s Current Report on Form 8-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 15, 2023). |
|---|
| 2023-05-12 | 10-Q | 10.4 | Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Chris Bitterman and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.14 of the Company’s Current Report on Form 8-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 15, 2023). |
|---|
| 2023-05-12 | 10-Q | 10.3 | Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Todd Anthony and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.13 of the Company’s Current Report on Form 8-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 15, 2023). |
|---|
| 2023-05-12 | 10-Q | 10.2 | Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Jim Herman and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.12 of the Company’s Current Report on Form 8-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 15, 2023). |
|---|
| 2023-05-12 | 10-Q | 10.1 | Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.11 of the Company’s Current Report on Form 8-K, File No. 001-33637, filed with the Securities and Exchange Commission on March 15, 2023). |
|---|
| 2023-03-15 | 8-K | 10.15 | Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between John M. Hamm and Cumberland Pharmaceuticals Inc. |
|---|
| 2023-03-15 | 8-K | 10.14 | Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Chris Bitterman and Cumberland Pharmaceuticals Inc. |
|---|
| 2023-03-15 | 8-K | 10.13 | Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Todd Anthony and Cumberland Pharmaceuticals Inc. |
|---|
| 2023-03-15 | 8-K | 10.12 | Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Jim Herman and Cumberland Pharmaceuticals Inc. |
|---|
| 2023-03-15 | 8-K | 10.11 | Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc. |
|---|
| 2023-03-13 | 10-K | 10.15 | Employment Agreement dated March 7, 2022, effective as of January 1, 2021, by and between James L. Herman and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.4 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on May 13, 2022 |
|---|
| 2023-03-13 | 10-K | 10.14 | Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between John M. Hamm and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.3 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on May 13, 2022 |
|---|
| 2023-03-13 | 10-K | 10.11 | Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on May 13, 2022 |
|---|